Emodin enhances cisplatin sensitivity in non-small cell lung cancer through Pgp downregulation

Peng,Shuai; Wang,Jincheng; Lu,Chang; Xu,Zelin; Chai,Jing-Jing; Ke,Qing; Deng,Xin-Zhou

doi:10.3892/ol.2021.12491

Emodin enhances cisplatin sensitivity in non-small cell lung cancer through Pgp downregulation

Authors:
- Shuai Peng
- Jincheng Wang
- Chang Lu
- Zelin Xu
- Jing-Jing Chai
- Qing Ke
- Xin-Zhou Deng
View Affiliations

Affiliations: Department of Clinical Medicine, Fourth Clinical College, Shiyan, Hubei 442000, P.R. China, Department of Clinical Medicine, Institute of Medicine and Nursing, Hubei University of Medicine, Shiyan, Hubei 442000, P.R. China, Department of Anesthesiology, Institute of Medicine and Nursing, Hubei University of Medicine, Shiyan, Hubei 442000, P.R. China, Department of Clinical Oncology, Taihe Hospital, Hubei University of Medicine, Shiyan, Hubei 442000, P.R. China, Department of Laboratory Medicine, Qingpu Branch of Zhongshan Hospital, Fudan University, Qingpu, Shanghai 201700, P.R. China
Published online on: January 26, 2021 https://doi.org/10.3892/ol.2021.12491
Article Number: 230
Copyright: © Peng et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Cisplatin resistance is one of the main causes of chemotherapy failure and tumor progression in non-small cell lung cancer (NSCLC). Emodin has been demonstrated to induce NSCLC cell apoptosis and act as a potential cancer therapeutic agent. However, whether emodin could affect NSCLC cell sensitivity toward cisplatin remains unclear. The present study aimed to determine the effect of emodin and cisplatin combination on the chemosensitivity of NSCLC cells. A549 and H460 cells were treated with different concentrations of cisplatin and/or emodin. Cell Counting Kit-8, fluorescence microscopy, immunofluorescence assays and flow cytometry were used to determine cell proliferation, drug efflux, DNA damage level and cell apoptosis, respectively. P-glycoprotein (Pgp) and multidrug resistance-associated protein 1 (MRP1) expression was detected by western blotting. The results demonstrated that emodin and cisplatin inhibited the proliferation of A549 and H460 cells. Furthermore, emodin inhibited the drug efflux in A549 and H460 cells in a dose-dependent manner. In addition, emodin enhanced cisplatin-induced apoptosis and DNA damage in A549 and H460 cells. Emodin also decreased Pgp expression in A549 and H460 cells in a dose-dependent manner; however, it had no effect on MRP1 expression. Taken together, the results from the present study demonstrated that emodin can increase A549 and H460 cell sensitivity to cisplatin by inhibiting Pgp expression. Emodin may therefore be considered as an effective adjuvant for cisplatin treatment.

View Figures

View References

1	Romaszko AM and Doboszyńska A: Multiple primary lung cancer: A literature review. Adv Clin Exp Med. 27:725–730. 2018. View Article : Google Scholar : PubMed/NCBI
2	Cheema PK, Rothenstein J, Melosky B, Brade A and Hirsh V: Perspectives on treatment advances for stage III locally advanced unresectable non-small-cell lung cancer. Curr Oncol. 26:37–42. 2019. View Article : Google Scholar : PubMed/NCBI
3	Driesen P, Lambrechts M, Kraaij K, Soldatenkova V, Chouaki N and Colinet B: A phase II single-arm study of induction chemotherapy with cisplatin and gemcitabine followed by concurrent cisplatin and gemcitabine with thoracic radiation for unresectable locally advanced non-small cell lung cancer. Ther Adv Med Oncol. 5:159–168. 2013. View Article : Google Scholar : PubMed/NCBI
4	Baldini E, Tibaldi C and Delli Paoli C: Chemo-radiotherapy integration in unresectable locally advanced non-small-cell lung cancer: A review. Clin Transl Oncol. 22:1681–1686. 2020. View Article : Google Scholar : PubMed/NCBI
5	Hauner K, Maisch P and Retz M: Side effects of chemotherapy. Urologe A. 56:472–479. 2017.(In German). View Article : Google Scholar : PubMed/NCBI
6	Pastorino G, Cornara L, Soares S, Rodrigues F and Oliveira MBPP: Liquorice (Glycyrrhiza glabra): A phytochemical and pharmacological review. Phytother Res. 32:2323–2339. 2018. View Article : Google Scholar : PubMed/NCBI
7	Wei WT, Lin SZ, Liu DL and Wang ZH: The distinct mechanisms of the antitumor activity of emodin in different types of cancer (Review). Oncol Rep. 30:2555–2562. 2013. View Article : Google Scholar : PubMed/NCBI
8	Li X, Shan C, Wu Z, Yu H, Yang A and Tan B: Emodin alleviated pulmonary inflammation in rats with LPS-induced acute lung injury through inhibiting the mTOR/HIF-1α/VEGF signaling pathway. Inflamm Res. 69:365–373. 2020. View Article : Google Scholar : PubMed/NCBI
9	Xu C, Zhang J, Liu J, Li Z, Liu Z, Luo Y, Xu Q, Wang M, Zhang G, Wang F, et al: Proteomic analysis reveals the protective effects of emodin on severe acute pancreatitis induced lung injury by inhibiting neutrophil proteases activity. J Proteomics. 220:1037602020. View Article : Google Scholar : PubMed/NCBI
10	Ma W, Liu C, Li J, Hao M, Ji Y and Zeng X: The effects of aloe emodin-mediated antimicrobial photodynamic therapy on drug-sensitive and resistant Candida albicans. Photochem Photobiol Sci. 19:485–494. 2020. View Article : Google Scholar : PubMed/NCBI
11	Chen Q, Li KT, Tian S, Yu TH, Yu LH, Lin HD and Bai DQ: Photodynamic therapy mediated by aloe-emodin inhibited angiogenesis and cell metastasis through activating MAPK signaling pathway on HUVECs. Technol Cancer Res Treat. 17:15330338187855122018. View Article : Google Scholar : PubMed/NCBI
12	Zu C, Qin G, Yang C, Liu N, He A, Zhang M and Zheng X: Low dose Emodin induces tumor senescence for boosting breast cancer chemotherapy via silencing NRARP. Biochem Biophys Res Commun. 505:973–978. 2018. View Article : Google Scholar : PubMed/NCBI
13	Fu M, Tang W, Liu JJ, Gong XQ, Kong L, Yao XM, Jing M, Cai FY, Li XT and Ju RJ: Combination of targeted daunorubicin liposomes and targeted emodin liposomes for treatment of invasive breast cancer. J Drug Target. 28:245–258. 2020. View Article : Google Scholar : PubMed/NCBI
14	Akev N, Candoken E and Erdem Kuruca S: Comparative study on the anticancer drug potential of a lectin purified from aloe vera and aloe-emodin. Asian Pac J Cancer Prev. 21:99–106. 2020. View Article : Google Scholar : PubMed/NCBI
15	Wang W, Sun Y, Li X, Li H, Chen Y, Tian Y, Yi J and Wang J: Emodin potentiates the anticancer effect of cisplatin on gallbladder cancer cells through the generation of reactive oxygen species and the inhibition of survivin expression. Oncol Rep. 26:1143–1148. 2011. View Article : Google Scholar : PubMed/NCBI
16	Chen Y, Gan D, Huang Q, Luo X, Lin D and Hu J: Emodin and Its combination with cytarabine induce apoptosis in resistant acute myeloid leukemia cells in vitro and in vivo. Cell Physiol Biochem. 48:2061–2073. 2018. View Article : Google Scholar : PubMed/NCBI
17	Chen S, Zhang Z and Zhang J: Emodin enhances antitumor effect of paclitaxel on human non-small-cell lung cancer cells in vitro and in vivo. Drug Des Devel Ther. 13:1145–1153. 2019. View Article : Google Scholar : PubMed/NCBI
18	Holford J, Beale PJ, Boxall FE, Sharp SY and Kelland LR: Mechanisms of drug resistance to the platinum complex ZD0473 in ovarian cancer cell lines. Eur J Cancer. 36:1984–1990. 2000. View Article : Google Scholar : PubMed/NCBI
19	Shi B, Xu FF, Xiang CP, Jia R, Yan CH, Ma SQ, Wang N, Wang AJ and Fan P: Effect of sodium butyrate on ABC transporters in lung cancer A549 and colorectal cancer HCT116 cells. Oncol Lett. 20:1482020. View Article : Google Scholar : PubMed/NCBI
20	Tian J, Hu J, Liu G, Yin H, Chen M, Miao P, Bai P and Yin J: Altered Gene expression of ABC transporters, nuclear receptors and oxidative stress signaling in zebrafish embryos exposed to CdTe quantum dots. Environ Pollut. 244:588–599. 2019. View Article : Google Scholar : PubMed/NCBI
21	Sauerborn Klobucar R, Zaja R, Franjević D, Brozović A and Smital T: Presence of ecotoxicologically relevant Pgp and MRP transcripts and proteins in Cyprinid fish. Arh Hig Rada Toksikol. 61:175–182. 2010. View Article : Google Scholar : PubMed/NCBI
22	Zhou J, Li Z, Li J, Gao B and Song W: Chemotherapy resistance molecular mechanism in small cell lung cancer. Curr Mol Med. 19:157–163. 2019. View Article : Google Scholar : PubMed/NCBI
23	Huang Y, Lei L and Liu Y: Propofol improves sensitivity of lung cancer cells to cisplatin and its mechanism. Med Sci Monit. 26:e9197862020. View Article : Google Scholar : PubMed/NCBI
24	Deng X, Hu Y, Ding Q, Han R, Guo Q, Qin J, Li J, Xiao R, Tian S, Hu W, et al: PEG10 plays a crucial role in human lung cancer proliferation, progression, prognosis and metastasis. Oncol Rep. 32:2159–2167. 2014. View Article : Google Scholar : PubMed/NCBI
25	Deng X, Tu Z, Xiong M, Tembo K, Zhou L, Liu P, Pan S, Xiong J, Yang X, Leng J, et al: Wnt5a and CCL25 promote adult T-cell acute lymphoblastic leukemia cell migration, invasion and metastasis. Oncotarget. 8:39033–39047. 2017. View Article : Google Scholar : PubMed/NCBI
26	Dong X, Luo Z, Wang Y, Meng L, Duan Q, Qiu L, Peng F and Shen L: Altered O-glycosylation is associated with inherent radioresistance and malignancy of human laryngeal carcinoma. Exp Cell Res. 362:302–310. 2018. View Article : Google Scholar : PubMed/NCBI
27	Xiao L, Tsutsui T and Miwa N: The lipophilic vitamin C derivative, 6-o-palmitoylascorbate, protects human lymphocytes, preferentially over ascorbate, against X-ray-induced DNA damage, lipid peroxidation, and protein carbonylation. Mol Cell Biochem. 394:247–259. 2014. View Article : Google Scholar : PubMed/NCBI
28	Dong W, Liao ZG, Zhao GW, Guan XJ, Zhang J, Liang XL and Yang M: Reversal effect of oxypeucedanin on P-glycoprotein-mediated drug transport. Molecules. 23:18412018. View Article : Google Scholar
29	Hurtado M, Sankpal UT, Chhabra J, Brown DT, Maram R, Patel R, Gurung RK, Simecka J, Holder AA and Basha R: Copper-tolfenamic acid: Evaluation of stability and anti-cancer activity. Invest New Drugs. 37:27–34. 2019. View Article : Google Scholar : PubMed/NCBI
30	Yang Y, Adebali O, Wu G, Selby CP, Chiou YY, Rashid N, Hu J, Hogenesch JB and Sancar A: Cisplatin-DNA adduct repair of transcribed genes is controlled by two circadian programs in mouse tissues. Proc Natl Acad Sci USA. 115:E4777–E4785. 2018. View Article : Google Scholar : PubMed/NCBI
31	Shah N, Liu Z, Tallman RM, Mohammad A, Sprowls SA, Saralkar PA, Vickers SD, Pinti MV, Gao W and Lockman PR: Drug resistance occurred in a newly characterized preclinical model of lung cancer brain metastasis. BMC Cancer. 20:2922020. View Article : Google Scholar : PubMed/NCBI
32	Li X, Wang H, Wang J, Chen Y, Yin X, Shi G, Li H, Hu Z and Liang X: Emodin enhances cisplatin-induced cytotoxicity in human bladder cancer cells through ROS elevation and MRP1 downregulation. BMC Cancer. 16:5782016. View Article : Google Scholar : PubMed/NCBI
33	Liu A, Chen H, Tong H, Ye S, Qiu M, Wang Z, Tan W, Liu J and Lin S: Emodin potentiates the antitumor effects of gemcitabine in pancreatic cancer cells via inhibition of nuclear factor-κB. Mol Med Rep. 4:221–227. 2011.PubMed/NCBI
34	Lin SZ, Wei WT, Chen H, Chen KJ, Tong HF, Wang ZH, Ni ZL, Liu HB, Guo HC and Liu DL: Antitumor activity of emodin against pancreatic cancer depends on its dual role: Promotion of apoptosis and suppression of angiogenesis. PLoS One. 7:e421462012. View Article : Google Scholar : PubMed/NCBI
35	Wang W, Sun YP, Huang XZ, He M, Chen YY, Shi GY, Li H, Yi J and Wang J: Emodin enhances sensitivity of gallbladder cancer cells to platinum drugs via glutathion depletion and MRP1 downregulation. Biochem Pharmacol. 79:1134–1140. 2010. View Article : Google Scholar : PubMed/NCBI
36	Tseng HS, Wang YF, Tzeng YM, Chen DR, Liao YF, Chiu HY and Hsieh WT: Aloe-emodin enhances tamoxifen cytotoxicity by suppressing Ras/ERK and PI3K/mTOR in breast cancer cells. Am J Chin Med. 45:337–350. 2017. View Article : Google Scholar : PubMed/NCBI
37	Jiang X, Lei T and Zhang M: Expression and functions of formyl peptide receptor 1 in drug-resistant bladder cancer. Technol Cancer Res Treat. 17:15330346187694132018. View Article : Google Scholar : PubMed/NCBI
38	Lee CH: Reversing agents for ATP-binding cassette drug transporters. Methods Mol Biol. 596:325–340. 2010. View Article : Google Scholar : PubMed/NCBI
39	Iyer VV, Priya PY and Kangeyavelu J: Effects of increased accumulation of doxorubicin due to emodin on efflux transporter and LRP1 expression in lung adenocarcinoma and colorectal carcinoma cells. Mol Cell Biochem. 449:91–104. 2018. View Article : Google Scholar : PubMed/NCBI